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Abstract Proteolysis of insulin-like growth factor binding
protein-3 (IGFBP-3), the major carrier of IGFs in the
circulation, is an essential mechanism to regulate IGF bioavail-
ability. To analyze naturally occurring IGFBP-3 fragments a
peptide library established from human hemofiltrate was
screened. Three IGFBP-3 fragments were detected with apparent
molecular masses of 34, 16, and 11 kDa. Mass spectrometric and
sequence analysis identified the 16 and 11 kDa peptides as
glycosylated and non-glycosylated N-terminal fragments span-
ning residues Gly1^Ala98 of IGFBP-3. Both the circulating forms
and those secreted from IGFBP-31ÿ98 overexpressing cells bound
IGF. Additionally, two smaller fragments (IGFBP-3139ÿ157 and
IGFBP-3139ÿ159) were identified in the hemofiltrate. The data
indicate that proteolysis of circulating IGFBP-3 occurs in the
variable domain at residues alanine 98, phenylalanine 138,
glutamine 157, and tyrosine 159. ß 2002 Published by Elsevier
Science B.V. on behalf of the Federation of European Biochem-
ical Societies.
Key words: Insulin-like growth factor binding protein-3;
Circulating fragment; Peptide library; Glycosylation
1. Introduction
The bioavailability of the insulin-like growth factors, IGF I
and IGF II, is modulated in the circulation and extracellular
environment by six di¡erent IGF binding proteins (IGFBP-1^
IGFBP-6) that bind IGFs with high a⁄nities [1,2]. In human
serum the majority of IGFs circulate as 150 kDa complex
consisting of IGFBP-3, an approximately 85 kDa acid-labile
subunit and IGF I or IGF II [3]. The ternary complexes
function as circulating reservoirs of IGFs and prolong the
half-lives of IGFs by preventing their clearance [4]. IGFBP-
3, the most abundant IGFBP, is found in serum as a charac-
teristic doublet of approximately 43^45 kDa consisting of two
di¡erentially glycosylated forms [5].
IGFs can be released from bi- and ternary IGF^IGFBP
complexes by limited proteolysis of IGFBPs resulting in the
generation of fragments with reduced a⁄nities for IGFs [6]. In
pregnancy serum IGFBP-3, -4, and -5 proteases have been
characterized and identi¢ed as disintegrin metalloprotease
ADAM 12S and PAPP-A [7^12]. Furthermore, elevated
IGFBP-3 protease activity has been shown under catabolic
and disease states, e.g. in patients with acute or chronic renal
failure or in diabetes [13^15]. The isolation of naturally occur-
ring fragments of IGFBP-4 and -5 in human hemo¢ltrate
(HF), the identi¢cation of cleavage sites, and their IGF bind-
ing properties [16,17] support the physiological signi¢cance of
IGFBP proteolysis.
In the present study we report on the puri¢cation and bio-
chemical characterization of IGFBP-3 fragments from human
HF allowing the delineation of IGFBP-3 protease cleavage
sites.
2. Materials and methods
2.1. Chromatographic isolation of IGFBP-3 fragments
A peptide library was generated from 10 000 l of HF as described
recently [18]. The lyophilized reversed phase (RP) fractions of human
HF were tested for IGFBP-3 immunoreactivity. Immunoreactive frac-
tions were pooled and subjected to further RP chromatography on a
C18 Prepak cartridge (300U47 mm inside diameter (i.d.), 30 nm, 15^
20 Wm, YMC, Schernbeck, Germany). Proteins were eluted using a
linear gradient (eluent A: 20:80 v/v MeOH/H2O, 0.1% TFA; eluent
B: 0.1% TFA in 100% MeOH) at a £ow rate of 40 ml/min. The most
intensive IGFBP-3 immunoreactive fractions were pooled and sepa-
rated by size-exclusion chromatography (140U920 mm i.d., Superdex
prepgrade 75, Pharmacia, Freiburg, Germany). The bu¡er used for
the isocratic elution was 200 mM ammonium formiate, pH 7.4, with a
£ow rate of 100 ml/min. Immunoreactive fractions were further en-
riched using cation-exchange chromatography (column of 150U30
mm i.d., Fractogel TSK Sp650 S, Merck, Darmstadt, Germany). Elu-
tion of proteins was performed using a linear NaCl gradient (bu¡er
A: 20 mM NaH2PO4, pH 5.0; bu¡er B: bu¡er A containing 1.5 M
NaCl; £ow rate: 10 ml/min; gradient: 0^50% bu¡er B within 40 min).
Final puri¢cation of immunoreactive fractions was carried out on an
analytical RP-C18 column (250U4.6 mm i.d., 30 nm, 5 Wm, ODS AQ,
YMC). Elution of proteins was achieved with a £ow rate of 0.7 ml/
min using a linear gradient (30^50% B within 60 min) with the above-
mentioned RP solvents.
2.2. SDS^PAGE and Western immunoblotting
Lyophilized aliquots of high performance liquid chromatography
(HPLC) fractions were reconstituted in non-reducing sample bu¡er,
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separated by TRICINE^SDS^PAGE [19], transferred to nitrocellulose
membranes (Trans-Blot, Bio-Rad, Munich, Germany) and incubated
with rabbit anti-IGFBP-3 antiserum (Upstate Biotechnology, Lake
Placid, NY, USA; 1:1 000) followed by anti-rabbit IgG coupled to
alkaline phosphatase (Sigma) or goat anti-rabbit IgG coupled to
horseradish peroxidase (HRP) (Dianova, Hamburg, Germany; 1:
10 000). Reactive bands were visualized using a bromochloroindolyl
phosphate/nitrotetrazolium substrate system (Sigma) or the SuperSig-
nal enhanced chemiluminescence (ECL) detection system (Pierce
Chemicals, Rockford, IL, USA).
2.3. Ligand blotting
After transfer of polypeptides to nitrocellulose, membranes were
incubated with phosphate-bu¡ered saline containing 1% bovine serum
albumin and 0.1% Tween 20 followed by incubation with 20 ng/ml
mono-biotinylated IGFs (mono-bIGFs; GroPep, Adelaide, Austra-
lia). IGF binding peptides were visualized by streptavidin-coupled
HRP (Jackson Immunoresearch, West Grove, PA, USA; 1:10 000)
and ECL.
2.4. Peptide analytics
Mass determination of peptides was performed by electrospray ion-
ization^mass spectrometry (ESI^MS) using a Sciex API III quadru-
pole mass spectrometer (Sciex, Perkin-Elmer, Langen, Germany) or
by matrix-assisted laser desorption ionization^mass spectrometry
(MALDI^MS; Voyager-DE STR, Perseptive Biosystems, Framing-
ham, MA, USA) as described previously [20,21]. The purity of iso-
lated IGFBP-3 peptides was investigated by capillary zone electropho-
resis and N-terminal sequencing was performed by conventional
Edman degradation as described recently [20].
2.5. Carbohydrate analysis
Peptides were incubated with neuraminidase (1 mU/Wl) and/or
N-glycosidase (1 mU/Wl) (Roche Diagnostics, Mannheim, Germany)
at 37‡C overnight and the reaction mixture was analyzed using an
HPLC^ESI^MS method as described recently [20]. Alternatively, the
polypeptides were transferred to nitrocellulose, blocked and incubated
with biotinylated concanavalin A (Sigma; 10 Wg/ml). The glycosylated
polypeptides were visualized by streptavidin-coupled HRP and ECL.
2.6. Generation of IGFBP-31ÿ98
Human IGFBP-3 cDNA in pBSK was a gift from J. Zapf (Zurich,
Switzerland). A 1.2 kb fragment was subcloned using £anking BglII
sites into BamHI predigested expression vector pcDNA3.1 (Invitro-
gen, Karlsruhe, Germany). The mutant IGFBP-31ÿ98 cDNA was gen-
erated by site-directed mutagenesis (QuikChange, Stratagene) using
the primer1 (5P-CGCCTGCGCGCCTAAGATCTGCCAGCGCCG-
3P) and primer2 (5P-CGGCGCTGGCAGATCTTAGGCGCGCAGG-
CG-3P) to introduce a stop codon (TAA) at the corresponding triplet
coding tyrosine residue 99 (TAC) and an additional BglII site for
restriction analysis. Oligonucleotides were synthesized by Nucleic
Acids Products Supply (Go«ttingen, Germany). The mutation was veri-
¢ed by sequencing.
2.7. Cell culture and transfection
The embryonic rat liver cell line RLC-18 was purchased from Deut-
sche Sammlung von Mikroorganismen und Zellkulturen (Braunsch-
weig, Germany). The cells were transfected with 10 Wg of plasmid
DNA using FUGENE 6 (Roche, Mannheim, Germany). Stable colo-
nies selected for the resistance against neomycin (Invitrogen) were
isolated and screened for IGFBP-3 fragment expression in media con-
ditioned for 48 h by IGFBP-3 Western blotting.
3. Results
Fractions of a peptide bank generated from 10 000 l of HF
[18,21] were tested for the presence of circulating fragments of
IGFBP-3. In the ¢rst step, peptides of the HF bound to a
cation-exchange column were eluted stepwise with eight bu¡-
ers of increasing pH (Fig. 1A) followed by fractionation of the
resulting pH pool eluates by RP-HPLC. When aliquots of
these RP fractions were analyzed by immunoblotting, three
prominent IGFBP-3 immunoreactive polypeptides of approx-
imately 34, 16, and 11 kDa were detected in fraction 23^26 of
pH pool 2 (not shown) and in fractions 23 and 24 of pH pool
3 (Fig. 1B). All three IGFBP-3 fragments bound IGF II as
shown by ligand blotting (Fig. 1C).
The immunoreactive IGFBP-3 fragment with an apparent
molecular mass of 16 kDa was subsequently puri¢ed by the
use of RP, size-exclusion, and cation-exchange chromatogra-
phy (data not shown) accompanied by IGFBP-3 immunoblot-
ting. A ¢nal analytical RP-chromatography resulted in a sin-
gle peak (Fig. 2A). N-terminal sequence analysis of this
fraction revealed GASSAGLGPVVRXEPX (X, unidenti¢ed
amino acids) proving the isolation of the N-terminal fragment
of human IGFBP-3. By MALDI^MS analysis (not shown)
and ESI^MS (Fig. 2B) the exact molecular mass of the puri-
Fig. 1. IGFBP-3 immunoblot-screening in fractions of a peptide li-
brary. A: After cation-exchange chromatography, bound peptides of
HF were batchwise eluted with increasing pH (pH pool fractions 1^
8). B: IGFBP-3 immunoreactive material was detected in fractions
derived from pH pool eluate 2 and 3. The RP-HPLC fractionation
pro¢le of the peptides from pH pool eluate 3 is shown. The frac-
tions 23 and 24 containing IGFBP-3 fragments (black bar) with ap-
parent molecular masses of 34, 16, and 11 kDa (insert) are marked.
C: Aliquots of each fraction collected by RP-HPLC chromatogra-
phy derived from pH pool 2 eluate were also tested by IGF II li-
gand blotting. The IGFBP-3 immunoreactive peptides of 34, 16,
and 11 kDa in the fractions 23^26 (black bars) bound also IGF II
(insert).
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¢ed IGFBP-3 fragment was calculated to be 12 266 þ 2.8 Da.
Neuraminidase treatment of this fraction resulted in a de-
crease in molecular mass of 582 Da to 11 685 þ 3.6 Da indi-
cating the removal of two N-acetyl neuraminic acid residues.
Further treatment with N-glycosidase F yielded in a polypep-
tide of 9 916 þ 1.1 Da (Fig. 2C) that was identical with the
theoretical mass of disul¢de bridged N-terminal IGFBP-3
fragment (residues 1^98) with an Ala residue in position 5.
This result was supported by the observation that reduction
and amido alkylation of this IGFBP-3 fragment increased the
molecular mass to 10 607 þ 9.9 Da corresponding to 12 alkyl-
ated cysteine residues (mass increase of 58 Da for each cys-
teine). The ESI^MS spectrum of the isolated IGFBP-3 frag-
ment with an apparent molecular mass of 11 kDa showed also
a molecular mass of 9 916 Da (not shown) suggesting that the
circulating 11 kDa IGFBP-3 fragment represents the deglyco-
sylated 16 kDa IGFBP-3 fragment. IGFBP-3 immunoblot
analysis of media from rat liver carcinoma cell line RLC-18
expressing the truncated human IGFBP-31ÿ98 revealed the
presence of 16 and 11 kDa IGFBP-3 fragments (Fig. 3) dem-
onstrating that the di¡erent electrophoretic mobilities of the
fragments were due to posttranslational modi¢cations. This
observation was supported by the ¢nding that the binding
of the lectin concanavalin A was restricted to the 16 kDa
but not to the 11 kDa IGFBP-3 fragment (Fig. 4). Addition-
ally, when the fraction 24 of pH eluate 3 was treated with
N-glycanase, the mass of the majority of the 16 kDa IGFBP-3
fragment was reduced to 11 kDa (not shown). Ligand blotting
experiments showed that both IGF I and IGF II bound to the
16 and 11 kDa IGFBP-3 fragments with similar intensity (Fig.
4). Two additional IGFBP-3 fragments comprising the amino
acid residues 139^157 and 139^159, were identi¢ed by system-
Fig. 2. A: Isolation of the 16 kDa IGFBP-3 fragment by analytical
RP-HPLC chromatography followed by Edman degradation. The
resulting N-terminal amino acid sequence is given. B: The ESI^MS
spectrum of the apparent 16 kDa N-terminal IGFBP-3 fragment re-
vealed a molecular mass of 12 266 þ 2.8 Da. C: The ESI^MS spec-
trum of the deglycosylated IGFBP-3 fragment revealed a molecular
mass of 9 916 þ 1.1 Da.
Fig. 3. IGFBP-3 immunoblot of recombinant IGFBP-31ÿ98. Ali-
quots of media from RLC-18 cells transfected with the human
IGFBP-31ÿ98 cDNA and of the fraction 24 of pH pool 3 eluate
were analyzed by Tricine SDS^PAGE and IGFBP-3 immunoblot-
ting.
Fig. 4. Glycosylation and IGF binding of IGFBP-3 fragments.
Equal aliquots of fraction 24 of pH pool 2 eluate were separated by
Tricine SDS^PAGE, transferred to nitrocellulose and analyzed ei-
ther by concanavalin A (bConA), bIGF I, bIGF II, or anti-IGFBP-
3 overlay and ECL.
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atic sequence analysis of peptides derived from the HF pH
pool 7 fraction.
4. Discussion
In the present study, the isolation and biochemical charac-
terization of circulating IGFBP-3 fragments derived from in
vivo proteolysis are described. Five IGFBP-3 fragments were
identi¢ed by immunoblotting (34, 16, and 11 kDa fragments)
and systematic peptide sequencing (2^2.5 kDa) of fractions
from a peptide library generated from human HF (Fig. 5).
The exact mass and cleavage sites of the 34 kDa IGFBP-3
fragment could not be determined. Treatment of a fraction
containing the 34 kDa fragment with N-glycanase under
non-reducing conditions decreased the size of the fragment
to a major band of 26 kDa and a minor band of 22 kDa
on SDS^PAGE analysis (B. Ku«bler, unpublished results).
Consistent with the ¢ndings that the mass of an N-linked
carbohydrate chain is approximately 4^5 kDa [5], our data
suggest that the 34 kDa IGFBP-3 fragment contains all three
N-glycosylation sites (N89, N109 and N172) which are not fully
accessible to N-glycanase. Zapf et al. [22] have also reported
on the isolation of a 30^32 kDa IGFBP from adult rat serum
with the N-terminal sequence of IGFBP-3 which has been
assumed to be a degradation product digestable with N-gly-
canase to a 26 kDa form.
Both the 16 and 11 kDa fragments contain the N-terminus
and comprise the amino acid residues 1^98 of IGFBP-3.
Whereas the 16 kDa IGFBP-3 fragment contains an N-linked
bi-antennary carbohydrate chain with two N-acetyl neura-
minic acid residues, the 11 kDa fragment represents a non-
glycosylated circulating IGFBP-31ÿ98 fragment. Proteolytic
modi¢cations of IGFBPs are thought to be a principle mech-
anism for regulating IGF availability and IGF-independent
functions of IGFBPs. Serum IGFBP-3 proteolysis has been
reported in severe illness, after surgery, in cancer patients, in
diabetes, and during pregnancy [8,15,23,24]. A disintegrin and
metalloprotease, presumably ADAM 12 S, is the most likely
candidate for the IGFBP-3 protease in pregnancy serum
[9,10]. However, several other neutral proteases such as the
prostate speci¢c antigen (PSA), plasmin, thrombin, matrix
metalloproteases (MMPs) as well as the acidic proteases ca-
thepsin D and L have been reported to function as IGFBP-3
proteases in vitro [25^29]. Sequence analysis revealed that
IGFBP-31ÿ97 is a major cleavage product of PSA, plasmin
and thrombin [25,26] and IGFBP-31ÿ99 is formed by MMP-
1 [27]. The isolation of the IGFBP-31ÿ98 fragment from HF
suggests that either none of these proteases are involved in the
proteolysis of circulating IGFBP-3, or the half-lives of the
generated fragments are signi¢cantly shorter. However, it
can not be excluded that the IGFBP-31ÿ98 fragment represents
an intermediate proteolytic product which might be further
modi¢ed by other endo- or carboxy peptidases. It is currently
unknown whether di¡erent serum proteases with distinct
cleaving site speci¢cities are responsible for proteolysis of
IGFBP-3 during pregnancy and catabolic states. The isolation
of the non-glycosylated IGFBP-31ÿ98 fragment was surprising
and its origin is unclear because aspartylglucosaminidases hy-
drolyzing complete carbohydrate chains from glycoproteins
are localized intracellularly [30] whereas successive terminal
deglycosylation of the intact or IGFBP-3 fragment would be
accompanied by rapid clearance form the circulation.
Both the glycosylated and non-glycosylated IGFBP-31ÿ98
bound IGFs which is consistent with the ¢ndings of other
laboratories that (i) N-terminal IGFBP-3 fragments bind
IGFs with reduced a⁄nities [31,32], and (ii) glycosylation of
the intact IGFBP-3 is not essential for IGF binding [5]. How-
ever, the IGFBP-31ÿ97 fragment generated by in vitro proteol-
ysis by plasmin expresses also IGF-independent bioactivities
such as inhibition of insulin receptor autophosphorylation
[31], and FGF-activated mitosis [33], or the stimulation of
glucose uptake in microvessel endothelial cells [34]. Whether
the isolated IGFBP-31ÿ98 fragment is biologically active too is
not known. Although the objective of this study was to isolate
and identify circulating IGFBP-3 fragments generated in vivo,
it will be interesting to investigate the modulation of IGF
activity by IGFBP-3 fragments in biological assays. The abil-
ity to express the IGFBP-31ÿ98 fragment in rat liver cells is an
initial step to examine its potential biological functions. An-
other question raised by our data concerned the role of
IGFBP-3 proteolysis in patients with end stage renal disease
used as source of the HF.
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